Drug Delivery Report
Welcome to drugdeliveryreport.com!
Established for over eleven years, the Drug Supply Report is relied upon throughout the industry as the principle methodology of independently assessing drug supply partners to allow drug supply deal making. drugdeliveryreport.com has been developed to make sure which you can entry up-to-the-minute drug supply deal making alternatives as well as key information and trends affecting the drug supply market.
Market news and developments
In August and September 2007, sixty four drug supply offers had been recorded in PharmaDeals® Agreements, 28 of which occurred in August. Licensing offers had been probably the most prolific of these, with 23 signed over the 2-month period. Considered one of these is a deal between BioDelivery Sciences International (BDSI) and Meda (Deal no. 28232) for the advertising and marketing of BEMA™ Fentanyl within the US, Canada and Mexico. This patented product has a unique delivery system designed to ship fentanyl for the therapy of breakthrough ache in cancer patients. BEMA™ Fentanyl consists of a small, dissolvable, polymer disc, formulated with the opioid narcotic fentanyl, for application to the buccal (inside lining of the cheek) membranes. This deal is price US$90 M, and is the biggest licensing deal on this interval concerned. The US$ninety M consists of an upfront fee of US$30 M made by Meda to BDSI on closing of the deal, US$30 M payable on product approval by the US FDA, and US$30 M in sales milestones made to Meda. BDSI has since received the preliminary (upfront) non-refundable milestone cost of US$30 M. The businesses may also collaborate on improvement for increasing the indication for BEMA™ Fentanyl.
Featured article - New-Technology Auto-Injectors: Finishing the Scale of Convenience for Self-injection
The marketplace for pens and auto-injectors continues to grow for the handy self-injection of biopharmaceuticals. Pre-stuffed syringes are becoming more and more widespread for self-injection and auto-injectors are serving to to simplify their use in new and present therapeutic areas. On this article, Ian Thompson of Ypsomed AG discusses the historical past of self-injection gadgets during the last twenty years and the development of recent and complicated gadgets, including Ypsomed's Auto-Injector, which works with the UltraSafe® Delivery System. Ian Thompson shows how such devices can be created in a variety of customised designs with a purpose to meet the needs of a variety of patient teams, safely and reliably.